ranQ
ranQ
ranQ
DirectoryIndustriesPlacesKnowledgeComparisonsSoon
Sign inCheck visibility
ranQHSG Startup LabelRecognised by the
HSG Startup Label

The leading AI company directory, built to boost AI visibility.

DEENFRIT
Product
  • Pricing
  • Directory
  • Industries
  • Trust Score
Company
  • About
  • Partner program
  • Contact
  • Legal
© 2026 cohaga AG · All Rights Reserved · St. Gallen, Switzerland · Imprint745,937 companies indexed · Last updated: today
DirectoryIndustryPharmaceutical IndustryBaselSwedish Orphan Biovitrum AG
Swedish Orphan Biovitrum AG Logo
Verified· 2 sourcesTrust Score
Summary

About the company

The company develops and distributes innovative treatments for rare diseases, particularly in the field of hematology, such as hemophilia and immune thrombocytopenia (ITP). The focus is on improving the lives of patients through access to new therapies and promoting patient-centricity and engagement.

AI-generated
Offering

Products & services

LeadhubOutbound Leads by COHAGA

Looking for direct email addresses and phone numbers?

Leadhub delivers verified contact details and decision-makers from over 750,000 Swiss companies — management, procurement, marketing, HR.

Discover Leadhub
4.1/5

Swedish Orphan Biovitrum AG

Industry:
Pharmaceutical Industry
✓ Offered8
Medicines
Medicines for the treatment and prevention of rare diseases, including haemophilia A and B, PNH, ITP, HLH, CAPS, FMF, HT-1, FCS and DLBCL.
Therapeutic areas
Haematology, immunology and specialty care, with focus on haemophilia, immune thrombocytopenia, paroxysmal nocturnal haemoglobinuria, rare genetic and metabolic diseases.
Access programmes
Managed access and emergency access to Sobi medicines for patients with serious or life-threatening rare diseases when alternatives or market access are limited.
Managed Access Programmes
Access to investigational medicines for eligible patients when no satisfactory alternatives exist and clinical trial enrolment is not possible, subject to local laws and review.
Clinical Trials
Patient-centred clinical trials and clinical research designed with patient input, transparent communication and inclusion in Sobi’s development programmes.
Research & development
Late-stage development of new therapies, expansion into new indications and geographies, and generation of real-world evidence in haematology and immunology.
Value added services
Patient support programmes and digital tools, including telemedicine, remote monitoring, home nursing, medicine delivery, patient navigation and adherence support.
Patient support programmes
Support programmes for people living with rare diseases, including digital tools, telemedicine, remote monitoring, home nursing and adherence support.
Trust & reputation

ranQ Trust Score of Swedish Orphan Biovitrum AG: 4.1 out of 5.0

Trust Score4.1/ 5.0

High

x

Data basis 54% · As of October 2026

Without public customer reviews the score stays capped.

Swedish Orphan Biovitrum AG has no value in the Reputation area of the ranQ Trust Score because no data is available. The area carries 42% of the weighting and drops out of the calculation for this profile; it does not lower the score, only the reported data basis.
x
CriterionValueWeight
  • Review quality: No data point — the criterion is taken out of the weighting and does not lower the score.—24%
  • Review volume: No data point — the criterion is taken out of the weighting and does not lower the score.—10%
  • Review recency: No data point — the criterion is taken out of the weighting and does not lower the score.—8%
Swedish Orphan Biovitrum AG scores 94.2 out of 100 points in the Substance area of the ranQ Trust Score. This area carries 28% of the weighting.
x
CriterionValueWeight
  • Establishment: Years since founding or brand launch, logarithmic. The maximum is reached at 15 years.92.512%
  • Company size: The headcount band, researched by ranQ or stated by the company. It is scored in steps rather than by head count, because the data only provides bands.96.07%
Swedish Orphan Biovitrum AG scores 85.0 out of 100 points in the Identity area of the ranQ Trust Score. This area carries 22% of the weighting.
x
CriterionValueWeight
  • Verification: Official register entry (commercial register with UID or professional-body record, 55 points), confirmed domain (20 points) and confirmed ranQ profile (up to 25 points, depending on completeness).85.022%
Swedish Orphan Biovitrum AG scores 100.0 out of 100 points in the Visibility area of the ranQ Trust Score. This area carries 8% of the weighting.
x
CriterionValueWeight
  • Website authority: Ahrefs' Domain Rating measures, on a scale of 0 to 100, how strongly a website is linked from other websites. For Swiss SMEs the range up to 40 is typical; the maximum is reached at 35.100.04%
  • Media authority: No data point — the criterion is taken out of the weighting and does not lower the score.—4%
Qualifications+0.00

Swedish Orphan Biovitrum AG reaches a ranQ Trust Score of 4.1 out of 5.0 — rated «High». No public customer reviews are available for this provider; the rating is based on the remaining criteria. The data basis is 54%, so the score is backed by part of the criteria. As of October 2026.

The Trust Score cannot be bought and is calculated from publicly verifiable data.

Knowledge

No knowledge articles yet

Once Swedish Orphan Biovitrum AG has claimed this profile, we'll publish editorial articles and case studies here together.

Get started
Comparisons

Swedish Orphan Biovitrum AG in comparison

Soon

Industry comparisons are coming soon

We're preparing industry comparisons that rank Swedish Orphan Biovitrum AG by reviews, experience and specialisations.

Is this your company?

Claim the company profile of Swedish Orphan Biovitrum AG to make its contact details visible. With a plan we additionally create and publish industry comparisons, articles and much more.

Secure profile

Location

Riehenring 182
4058 Basel
Opening hours
Mon
08:00 - 17:00
Tue
08:00 - 17:00
Wed
08:00 - 17:00
Thu
08:00 - 17:00
Fri
08:00 - 17:00
Sat
Closed
Sun
Closed

At a glance

Legal form
Corporation
UID
CHE-284.917.678
Founded
2014 · 12 years
Last commercial register change
October 15, 2025
Employees
101 to 500
Legal form: Graded by liability and disclosure. The weight is kept small: a sole proprietorship is not a dubious company, it is just liable differently.
100.0
6%
  • Branch offices: Branch offices linked in the commercial register. Having none is normal and costs no points.85.03%
    • Full methodology

    Similar companies

    RC
    Roche Chemische Unternehmungen AG
    Basel
    NP
    Novartis Pharma AG
    Basel
    BM
    BeOne Medicines I GmbH
    Basel
    BI
    Boehringer Ingelheim (Schweiz) GmbH
    Basel
    LB
    Luzsana Biotechnology Europe AG
    Basel
    RS
    Regeneron Switzerland GmbH
    Basel
    US
    Urovant Sciences GmbH
    Basel
    VT
    Vaderis Therapeutics AG
    Basel